Lixiao Xing

STING agonist-based ER-targeting molecules boost antigen cross-presentation

Xiafeng Wang, Zhangping Huang, Lixiao Xing et al. · Nature · 2025 · 60 citations · Full text

Medicine, Immunology, Oncology +17

A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of Concern

Lixiao Xing, Xinfeng Xu, Wei Xu et al. · Viruses · 2022 · 42 citations · Full text

Life Sciences, Infectious Diseases, Molecular Virology +11

Early fusion intermediate of ACE2-using coronavirus spike acting as an antiviral target

Lixiao Xing, Zhimin Liu, Xinling Wang et al. · Cell · 2025 · 41 citations

Life Sciences, Infectious Diseases, Molecular Biology +16

A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases

Jie Zhou, Wei Xu, Zezhong Liu et al. · Acta Pharmaceutica Sinica B · 2021 · 36 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen

Xinling Wang, Lujia Sun, Zezhong Liu et al. · Emerging Microbes & Infections · 2023 · 23 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +16